Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation

Flor M. Munoz, Janet A. Englund, Coni C. Cheesman, Maurizio L. Maccato, Phillip M. Pinell, Moon H. Nahm, Edward Mason, Claudia A. Kozinetz, Rachel A. Thompson, W. Paul Glezen

Research output: Contribution to journalArticle

84 Scopus citations

Abstract

In a randomized, double blinded study, 23-valent pneumococcal polysaccharide vaccine (PSV) or conjugate Haemophilus influenzae type b (HbOC) vaccine was administered to 60 healthy women in the third trimester of gestation. Total IgG, IgG1, and IgG2 antibodies to pneumococcal serotypes 6B, 14, 19F and 23F were measured by ELISA in mothers prior to immunization, at delivery and 7 months after delivery, and in infants at birth (cord blood), 2 and 7 months after delivery. IgA was evaluated in breast milk at 2 and 7 months, and opsonophagocytic activity in cord blood. PSV was safe and immunogenic in pregnant women. Transplacental transmission of vaccine-specific antibodies was efficient. Maternal immunization with PSV resulted in significantly higher concentrations of pneumococcal antibodies in infants at birth and at 2 months of age, and greater functional opsonophagocytic activity of passively acquired IgG antibody.

Original languageEnglish (US)
Pages (from-to)826-837
Number of pages12
JournalVaccine
Volume20
Issue number5-6
DOIs
StatePublished - Dec 12 2001

Keywords

  • Maternal immunization
  • Opsonophagocytosis
  • Pneumococcal vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Fingerprint Dive into the research topics of 'Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation'. Together they form a unique fingerprint.

Cite this